01—Abstract
Summary
Summary of the 8-K filed January 8, 2024. Cited figures are marked; the original filing is the authoritative source.
Danaher Corporation (NYSE: DHR) furnished an 8-K on January 8, 2024, ahead of CEO Rainer M.
Blair's presentation at the J.P. Morgan Healthcare Conference on January 9, 2024. The company provided a preliminary read on fourth-quarter 2023 performance: total revenue is estimated to decline in the low-double-digit percent range year over year.
Non-GAAP core revenue is expected to fall in the low-double-digit range, which is better than the previously guided high-teens percent decline. Base business core revenue is expected to decline in the mid-single-digit range, in line with prior guidance. The decline is driven largely by the post-pandemic normalization of COVID-19 testing, vaccine, and therapeutics demand, partly offset by currency and acquisitions.
Management indicated that Q4 results were better than anticipated in a challenging operating environment. Life Sciences and Biotechnology both modestly exceeded expectations, and respiratory revenue at Cepheid topped $600 milliona, above expectations. Management expects Q4 2023 adjusted operating profit margin to be in line with or above the prior guidance of roughly 28%.
The Abcam acquisition closed in December 2023, ahead of the company's initial timeline. The presentation frames Danaher's portfolio transformation since 2018, when it had roughly $24 billionb in revenue, including exits of Dental and Environmental & Applied Solutions and the divestiture of Cytiva.
The company now targets roughly $20 billionc in 2023E revenue, with a stronger mix toward Diagnostics and Life Sciences, and about 80% recurring revenue. Investors should note that the company did not provide full-year 2024 guidance in this filing, and that the figures are preliminary estimates subject to the upcoming Q4 earnings call on January 30, 2024.
02—Key points
Key Highlights
- Q4 2023 total revenue estimated to decline in the low-double-digit percent range year over year (GAAP basis).
- Non-GAAP core revenue expected to decline in the low-double-digit range, better than the previously guided high-teens percent decline.
- Base business core revenue expected to decline mid-single digits, in line with previous guidance.
- Cepheid respiratory revenue exceeded $600 million in Q4, above management's expectations.
- Life Sciences and Biotechnology segments both modestly exceeded expectations; Q4 adjusted operating margin expected at or above the ~28% prior guidance.
- Abcam acquisition closed in December 2023, earlier than the company's initial expectations.
- Quarterly earnings call for Q4 and full-year 2023 scheduled for January 30, 2024, at 8:00 a.m. ET.
03—Questions
Frequently Asked Questions
Why is Danaher's revenue declining in Q4 2023?
The decline is driven mainly by the normalization of COVID-19 demand. Demand for COVID-19 testing, vaccines, and therapeutics has moderated as the pandemic became endemic. Currency exchange rates added a low-single-digit headwind, while acquisitions and divestitures were essentially flat. Excluding these items, the base business declined mid-single digits.
Did Danaher beat or miss expectations for Q4 2023?
Based on this preliminary disclosure, Danaher reported better-than-anticipated results. Core revenue came in above the previously guided high-teens decline, Cepheid respiratory revenue exceeded expectations, and the Life Sciences and Biotechnology segments were modestly ahead of plan. Base business core revenue was in line with guidance.
What does the Abcam acquisition mean for Danaher?
The Abcam acquisition closed in December 2023, ahead of the company's initial timeline. This strengthens Danaher's Life Sciences portfolio. Because acquisition effects are excluded from core revenue, the near-term impact on core growth metrics is limited, and the longer-term benefit depends on successful integration and realized synergies.
Is Danaher providing 2024 guidance in this filing?
No. This 8-K covers only preliminary Q4 and 2023 full-year estimates. Investors should look to the January 30, 2024 earnings call and the subsequent Form 10-K for detailed 2024 outlook and full-year financial results.
04—Continue